Retrospective Comparitive Analytical Study Of Biological Behaviour Of Breast Cancer Based On Hormonal Status In Premenopausal And Post Menopausal Women

Abstract

Breast tissue is cyclically dependent on hormones. Hormone receptor status is important in deciding the choice of treatment for all subgroups of breast cancer and influences the quality of life. The purpose of this study is to compare the biological behaviour of breast cancers based on hormonal receptor status in premenopausal and postmenopausal women as they have significant differences in tumour size, tumour grade, axillary lymph node metastasis, hormone receptor status, human epidermal receptor-2 expression, and treatment modalities. There is also importance of psychological status assessment secondary to cancer diagnosis and treatment, hence careful examination of symptoms and psychosocial needs is mandatory in oncology and palliative care settings. A Retrospective cohort study was carried out in Department of Radiotherapy, Government General Hospital, Guntur for a period of 6 months i.e.,2021 to 2022 after obtaining approval from Institutional Ethics Committee.  The hormonal receptor status [ER/PR/HER-2] in breast cancer was assessed based on pathology reports and are categorized into 5 groups i.e., 1)ER/PR/HER2- positive  2)ER/PR/HER2negative  3)ER/PR-positive /HER2- negative 4) ER/PR-negative/HER2-positive 5) Others.  Validated questionnaire (EORTC QLQ-BR23 , HADS, SF-36) was used to assess the quality of life in breast cancer patients. 146 patients who met the inclusion criteria  were included in the study.The data obtained was tabulated and  analysed the quality of life of the patient using t-test(P=0.027) and found that there is  improvement in both functional status and psychosocial status; the difference is found to be statistically significant which indicates that there is improvement in quality of life of the patient before and after providing the therapy. Based on the results obtained in our study. We strongly conclude that  irrespective of the menopausal state and stage at the time of diagnosis , majority of the patients were diagnosed with receptor status ER-PR: +VE, HER2: -VE (n=31 , 21.23%).